<DOC>
	<DOC>NCT02976142</DOC>
	<brief_summary>The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in patients with gastric cancer and verified free cancer cells in abdominal cavity in improving the long term outcomes and overall survival of further surgical treatment.</brief_summary>
	<brief_title>The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>ECOG 02 Histologically proven gastric cancer T23 N+, T4a with any N (0,+) with free cancer cells in the abdominal cavity and no macroscopic canceromathosis and no other distant metastases (TNM classification 7th edition) Histological forms: gastric adenocarcinoma and signet ring cancer Blood characteristics (creatinine &lt;150 mg/l, total bilirubin &lt; 50 mkmol/l, neutrophils &lt; 1500/mkl, hemoglobin &gt;90 g/l, thrombocytes &gt; 100000/mkl) Clinically apparent distant metastasis (besides free cancer cells) Synchronic or metachronic malignant tumors Previous systemic or surgical or combined therapy for gastric cancer Complications of gastric cancer (obstruction 01 GOOSS scale and/or gastric bleeding) Adhesions in abdominal cavity Gastrooesophageal junction cancer or gastric cancer with spreading on oesophagus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>gastric cancer, metastatic</keyword>
	<keyword>positive wash cytology</keyword>
	<keyword>neoadjuvant intraperitoneal immunotherapy</keyword>
</DOC>